home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.76 -0.32 (-0.68%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

41 42 Next >

Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch ↗

January 29, 2023

With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.

Via Benzinga

Could This Vaccine Become Sanofi's Latest Blockbuster? ↗

January 29, 2023

This vaccine candidate could be approved in newborns and infants later this year.

Via The Motley Fool

Hopeful Golden Cross Forms On Sanofi's Chart ↗

January 26, 2023

Via Benzinga

What Does Sanofi's Debt Look Like? ↗

January 06, 2023

Over the past three months, shares of Sanofi Inc. (NASDAQ:SNY) increased by 20.92%. Before having a look at the importance of debt, let's look at how much debt Sanofi has.

Via Benzinga

Sanofi Forecasts Foreign Exchange, Record Flu Vaccine Sales To Boost Q4 Earnings ↗

January 04, 2023

Via Benzinga

7 Blue-Chip Stocks to Buy as a New Bull Market Emerges ↗

January 26, 2023

Many blue-chip stocks look like a bargain right now, and these seven companies are certainly no exception.

Via InvestorPlace

Mergers and Acquisitions in 2023 Off To A Strong Start

January 26, 2023

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

Via MarketBeat

Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023 ↗

January 23, 2023

It's difficult to imagine a future where healthcare isn't in high demand.

Via The Motley Fool

Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market ↗

January 19, 2023

After years of lab failures, the companies could crack open a multibillion-dollar market.

Via Investor's Business Daily

The Viral “Tripledemic” Opportunity ↗

January 14, 2023

Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu...

Via Talk Markets

Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot ↗

January 13, 2023

Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand.

Via Benzinga

Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics ↗

January 09, 2023

Via Benzinga

What This Drug News Could Mean for Sanofi Shareholders ↗

January 08, 2023

This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.

Via The Motley Fool

5 Top Pharma Stocks of 2022 to Buy for the Long Haul ↗

January 06, 2023

The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks.

Via InvestorPlace

FDA Permits Pharmacies To Distribute Abortion Pills, Tesla's Aggressive Discounting May Have Hit Gross Margins, Goldman Sachs Bullish On M&A Activity In Late 2023: Top Stories Today ↗

January 04, 2023

Reuters Goldman Sachs Bullish On M&A Deals Activity Picking Up In Late 2023

Via Benzinga

Could This Drug News Give a Lift to Eli Lilly Stock? ↗

January 01, 2023

In November, Eli Lilly received positive news from the U.S. Food and Drug Administration.

Via The Motley Fool

3 Medical Dividend Stocks That Hit the Sweet Spot ↗

December 26, 2022

These three offer high dividend yields and consistent revenue growth.

Via The Motley Fool

After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs ↗

December 19, 2022

Via Benzinga

Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology

December 19, 2022

From Innate Pharma SA

Via Business Wire

Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review ↗

December 16, 2022

Moderna spiked on a cancer vaccine while Tesla continued to dive.

Via Investor's Business Daily

2 Best Biotech Stocks to Buy Right Now ↗

December 16, 2022

Demand for medicines and vaccines has nowhere to go but up over the long run.

Via The Motley Fool

Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis ↗

December 15, 2022

Via Benzinga

These Biotech Stocks Are the Nasdaq's Big Wednesday Winners ↗

December 14, 2022

Business wins are shining the spotlight on these two companies.

Via The Motley Fool

Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today? ↗

December 14, 2022

KYMR stock traders are bidding up the share price today as Kymera Therapeutics teams up to take a skin condition treatment to the next phase.

Via InvestorPlace

Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial ↗

December 14, 2022

Via Benzinga

Why Small Biotech Kymera Just Snagged Sanofi's Interest And Surged 28% ↗

December 14, 2022

The company is working on protein degradation in cancer and inflammatory diseases.

Via Investor's Business Daily

Horizon Therapeutics (HZNP) Stock Pops on HUGE Amgen Deal ↗

December 12, 2022

HZNP stock is up on news that Horizon Therapeutics is being bought by Amgen in a friendly deal that's positive for both companies.

Via InvestorPlace

Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal ↗

December 12, 2022

The deal comes a day after Sanofi dropped out of the bidding process.

Via Investor's Business Daily

Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12 ↗

December 12, 2022

Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU

Via Benzinga

Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share ↗

December 12, 2022

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com